熱點掃描 |
uSMART盈立智投4月8日消息，截止發稿，港股三大指數漲跌互現，恆生指數下跌0.44%，報21715.55點，成交額483.14億；國企指數下跌0.92%，報7426.42點，成交額170.12億；紅籌指數上漲0.97%，報4073.41點，成交額21.51億。
高鐵基建股漲幅居前，中國中鐵漲超7%，中國中冶、中國鐵建漲超5%，中國交通建設漲超3%；
黃金股普漲，中國黃金國際漲超5%，山東黃金漲逾4%，山東黃金、靈寶黃金上漲3%，招金礦業漲超2%；
煤炭股延續昨日漲勢，伊泰煤炭漲近6%，兗礦能源、易大宗漲超3%，中煤能源上漲2.25%，中國神華漲近2%；
手遊股普跌，心動公司跌超7%，創夢天地跌3.17%，金山軟件跌3%，騰訊控股跌1.34%；
體育用品股走低，安踏體育跌超5%，李寧跌近7%，滔搏跌4.17%。
熱門股
開拓藥業盤中再度拉昇漲超14.29%至24.85港元。公司4月6日公佈普克魯胺全球輕中症三期臨牀數據，反映顯著的療效訊號，且入組者不限受試者疫苗接種狀態，及基礎疾病等情況。公司並將在之後4-6周內進一步完成所有數據分析，並可能基於完整的數據結果向中國、美國、歐盟和其他國家監管機構遞交緊急使用授權(EUA)申請。消息公佈當天該股股價翻倍。招銀國際最新研報維持其買入評級，目標價由34.37港元上調至48.78港元，看好其新冠口服藥普克魯胺治療潛力；
中國能源建設逆勢漲6.31%，報1.18港元，中國能源建設A股亦漲2%報2.5元。天風證券研報稱，新能源運營顯示成長彈性，公司在手訂單充足。“十四五”期間公司控股新能源裝機容量預計將達到2000 萬千瓦以上。去年公司新籤合同額高速增長，爲公司後續收入利潤的增長提供了有力保障；
朗生醫藥漲15%，報1.25港元。該公司昨日公佈，於2022年4月7日，公司擬向不少於6名承配人發行合共4952萬股配售股份，佔經擴大後公司股份約11.60%。每股配售價爲1.20港元，較4月7日收市價溢價約11.1%。所得款項總額及淨額預期將分別約爲5942萬港元及5915萬港元。公司擬將該等所得款項淨額用於(i)潛在的未來併購或項目；及(ii)補充營運資金及一般企業用途，以支持公司策略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
